东亚药业
(605177)
| 流通市值：20.60亿 | | | 总市值：21.00亿 |
| 流通股本：1.13亿 | | | 总股本：1.15亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 963,019,242.47 | 648,226,520.15 | 352,582,674.1 | 1,356,448,097.16 |
| 营业收入 | 963,019,242.47 | 648,226,520.15 | 352,582,674.1 | 1,356,448,097.16 |
| 二、营业总成本 | 914,079,555.24 | 614,661,764.74 | 326,656,986.63 | 1,229,896,097.02 |
| 营业成本 | 703,230,309.84 | 480,912,437 | 263,022,490.14 | 995,092,507.87 |
| 税金及附加 | 8,539,592.24 | 4,444,363.27 | 2,195,494.95 | 9,990,045.09 |
| 销售费用 | 10,982,915.66 | 7,731,959.02 | 2,667,587.64 | 13,826,393.48 |
| 管理费用 | 127,438,407.37 | 80,124,809.87 | 40,657,303.31 | 137,159,491.03 |
| 研发费用 | 67,140,483.98 | 43,529,401.21 | 19,280,144.23 | 81,737,634.3 |
| 财务费用 | -3,252,153.85 | -2,081,205.63 | -1,166,033.64 | -7,909,974.75 |
| 其中:利息费用 | 2,478,028.51 | 1,279,456.7 | 711,807.01 | 3,598,551.43 |
| 其中:利息收入 | 4,289,818.64 | 2,163,246.03 | 1,532,162.9 | 11,230,923.1 |
| 加:投资收益 | 3,342,771.63 | 2,870,424.43 | 1,898,318.24 | 7,028,807.9 |
| 资产处置收益 | -90,624.45 | -51,637.15 | -3,257.83 | -2,250,572.3 |
| 资产减值损失(新) | -3,552,573.56 | -2,570,631.01 | -465,420.35 | -8,471,811.1 |
| 信用减值损失(新) | -3,315,686.94 | -2,058,717.13 | -4,848,150.68 | -3,015,585.09 |
| 其他收益 | 14,544,601.08 | 10,550,336.02 | 6,082,668.3 | 17,127,674.07 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 59,868,174.99 | 42,304,530.57 | 28,589,845.15 | 136,970,513.62 |
| 加:营业外收入 | 30,148 | 30,148 | - | 3,202,623.94 |
| 减:营业外支出 | 4,445,608.27 | 3,167,895.96 | 623,454.5 | 5,482,236.65 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 55,452,714.72 | 39,166,782.61 | 27,966,390.65 | 134,690,900.91 |
| 减:所得税费用 | 10,296,716.32 | 6,701,969.59 | 3,927,192.61 | 13,441,501.41 |
| 六、净利润 | 45,155,998.4 | 32,464,813.02 | 24,039,198.04 | 121,249,399.5 |
| 持续经营净利润 | 45,155,998.4 | 32,464,813.02 | 24,039,198.04 | 121,249,399.5 |
| 归属于母公司股东的净利润 | 45,169,152.65 | 32,473,045.75 | 24,039,198.04 | 121,249,399.5 |
| 少数股东损益 | -13,154.25 | -8,232.73 | - | - |
| (一)基本每股收益 | 0.4 | 0.29 | 0.21 | 1.07 |
| (二)稀释每股收益 | 0.31 | 0.22 | 0.16 | 0.97 |
| 八、其他综合收益 | - | - | - | 418,781.05 |
| 归属于母公司股东的其他综合收益 | - | - | - | 418,781.05 |
| 九、综合收益总额 | 45,155,998.4 | 32,464,813.02 | 24,039,198.04 | 121,668,180.55 |
| 归属于母公司股东的综合收益总额 | 45,169,152.65 | 32,473,045.75 | 24,039,198.04 | 121,668,180.55 |
| 归属于少数股东的综合收益总额 | -13,154.25 | -8,232.73 | - | - |
| 公告日期 | 2024-10-31 | 2024-08-30 | 2024-04-30 | 2024-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |